Known as a general anthelmintic in veterinary medicine since the late 1970s, oxfendazole became a focus for the mid 1990s studies of the Cysticercosis Working Group in Peru. Their field trials on the management of cysticercosis in rural communities revealed that oxfendazole was far better in pigs than had been expected, with near complete elimination of the parasite, leading to consideration of oxfendazole as a possible treatment for cysticercosis in humans. The veterinary data further suggested a broad potential for the drug in the treatment of human parasitic diseases.
Growing organically out of the work of the Cysticercosis Working Group in Peru, the Oxfendazole Development Group incorporated as a Pennsylvania nonprofit and a US 501(c)(3) organization in 2016, with the aim of bringing oxfendazole through development to registration as treatment for several neglected parasitic diseases in humans. Its Founders included some who led the groundbreaking pharmacologic work (Armando Gonzalez, Héctor Hugo Garcia, Robert Gilman) as well as others who had pharmaceutical drug development expertise (John Horton, Ellen Codd). Beginning with the toxicology studies required by regulatory authorities worldwide prior to first-in-human evaluation of a new drug, we moved on to Phase 1 single and then multiple ascending dose studies of oxfendazole in healthy human volunteers, with both the toxicology studies and Phase 1 clinical trials funded by the Division of Microbiology and Infectious Diseases of the US National Institutes of Heath. Receipt of generous grants from ACX and Open Philanthropy (now Coefficient Giving), enabled the conduct of nonclinical safety pharmacology and additional toxicology studies.
With the first Phase 2 study in patients in Peru nearing completion and two others about to initiate, we are seeking funding for Phase 3 enabling studies (reproductive toxicology studies and the formulation and manufacture of oxfendazole tablets) to enable initiation of the Phase 3 clinical trials needed for registration.
